The optimal duration and type of antiplatelet therapy after implantation of a drug-eluting stent (DES) remains uncertain. In this Review, Miyazaki et al. summarize the evidence on the duration of dual antiplatelet therapy and the risk of bleeding and adverse cardiac events after DES implantation, and describe the pitfalls of trial interpretation. Ongoing trials to test single antiplatelet therapy after DES implantation are also discussed.
- Yosuke Miyazaki
- Pannipa Suwannasom
- Patrick W. Serruys
